BEST UNLIMITED TURBO LONG CERTIFICATE - ABBVIE | Market Closed - Euronext Paris 17:30:01 02/05/2024 BST | ||
| 8.648 EUR | -7.82% |
|
| Current month | -6.90% | ||
| 1 month | -30.50% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ABBVIE INC.
Latest news about ABBVIE INC.
More news
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/05/24 | 8.648 | -7.82% | 45 |
| 30/04/24 | 9.382 | +5.81% | 45 |
| 29/04/24 | 8.867 | +1.60% | 60 |
| 26/04/24 | 8.727 | -14.76% | 77 |
| 25/04/24 | 10.24 | -1.68% | 83 |
Real-time Euronext Paris
Last update May 02, 2024 at 05:30 pm
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ABBVIE INC. |
| Issuer | 
Société Générale
|
| PA12S | |
| ISIN | DE000SF4VFK8 |
| Date issued | 22/09/2021 |
| Strike | 114.4 $ |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 1.2 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 13.63 € |
|---|---|
| Lowest since issue | 1.14 € |
Company Profile
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease.
Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).
Sector
-
Consensus: AbbVie Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
27
Last Close Price
161.7
USD
Average target price
182.3
USD
Spread / Average Target
+12.73%
- Stock Market
- Certificates
- PA12S Certificat
